AJJ MEDTECH HOLDINGS LIMITED
(Company Registration No.: 198403368H)
(Incorporated in the Republic of Singapore)

RESPONSES TO SGX QUERIES

The Board of Directors (the "**Board**" or the "**Directors**") of AJJ Medtech Holdings Limited (the "**Company**", and together with its subsidiaries, the "**Group**") refers to the following queries by the Singapore Exchange Securities Trading Limited (the "**SGX-ST**") on 11 Aug 2026. Unless otherwise defined, capitalised terms used in this announcement shall have the meanings ascribed to them in the Company's announcements dated 30 June 2025 relating to the Notice of Termination of Distributorship Agreement.

<u>QUERIES</u>

We note that Chong Eng Wee is appointed as a Director of the Company. He was also recently appointed to the Board of Unusual Limited ("UL") on 3 August 2026 and is currently a director of nine listed companies in total. Other than the above, he has principal commitments in respect of five non-listed companies.

In response to SGX RegCo's compliance query to UL as announced on 7 August 2026, UL represented among others that Mr Chong shall retire as the Non-Executive and Independent Chairman of a SGX-listed company at its next annual general meeting ("AGM"), and he also does not intend to stand for re-election as a Non-Executive and Independent Director of another SGX-listed company at its next AGM.

(a) Provision 4.5 of the Code of Corporate Governance requires the Company's Nominating Committee ("NC") to determine if a director is able to and has been adequately carrying out his or her duties as a director of the company. Where a director holds a significant number of directorships and principal commitments, the NC and the Board must provide a reasoned assessment of the ability of the director to diligently discharge his or her duties.

Please provide the detailed bases for the Board and NC's assessment on whether Mr Chong will be able to carry out his duties as a Director of the Company effectively, considering his other competing commitments (including multiple board representations).

Company's Response:

In assessing Mr. Chong's ability to discharge his duties effectively notwithstanding his other principal commitments and board appointments, the Board and the NC (with Mr. Chong abstaining from deliberations) understand from Mr. Chong and/or took into account, among the following:

(i) other than his directorships at listed companies, Mr Chong's principal commitments at non-listed companies primarily comprise his legal practice as Managing Director of Chevalier Law LLC ("CLL") and as Partner of Nixon Peabody CWL ("NPCWL") which constitute 2 out of his directorships at non-listed companies. The remaining 3 directorships at non-listed companies pertain to him acting in a nominee local director capacity and/or being a director for a dormant company;

(ii) Mr Chong's legal practice at CLL and NPCWL primarily involves business development, origination and/or management duties, and he is supported by other lawyers at CLL and NPCWL who are responsible for execution of client matters. The NC and the Board understand that this allows Mr Chong to plan his professional commitments for CLL and/or NPCWL around Board and Board committee meetings of the Company which are often scheduled in advance. Mr Chong has also demonstrated that he is available and responsive beyond formal meetings when matters and/or affairs of the Company require his attention.;

(iii) Mr Chong has approximately 20 years of legal experience in capital markets, mergers and acquisitions, private equity and regulatory compliance matters, and is admitted to practice in multiple jurisdictions. His familiarity with the SGX-ST Listing Rules and applicable Singapore laws, together with his extensive experience as an independent director and/or chairman of other SGX-ST and Hong Kong-listed companies, allows him to contribute substantially to the Company's corporate governance, risk management and regulatory compliance needs, and to be well placed to provide valuable input in the aforesaid areas and in exercising board oversight, enabling him to contribute effectively to the Company;

(iv) The Board and NC have considered Mr Chong's actual performance and participation in the Company's affairs since his appointment as an Independent and Non-Executive Director ("INED") since June 2020. Through his frequent interactions, discussions and meetings with management, the Board and the NC noted that Mr. Chong has acquired in-depth knowledge of the Company's history, business, corporate developments and industry outlook including the challenges and risks associated with the medtech industry. The above, coupled with Mr. Chong's ability to communicate in both English and Chinese, enables him to be efficient and effective in communicating with the management and other Board members;

(v) In addition to his full attendance record, Mr Chong has consistently prepared diligently for meetings, responded promptly to Company matters and devoted sufficient time and attention to the affairs of the Board and the Company's corporate governance. During periods involving shareholder disputes, he provided legal and governance guidance to assist the Company in safeguarding its legitimate interests, maintaining the proper functioning of the Board and upholding due decision-making processes. Drawing on his legal expertise, he has also assisted the Company in identifying, assessing and managing relevant risks, including those arising from AJJ Medtech's transformation into a medical technology company. The Board and the NC consider that his contributions have supported the Company's corporate stability, risk control and sustainable development, and that he has consistently acted in the interests of the Company and its shareholders as a whole.

(vi) Based on Mr. Chong's full attendance at Board, Board Committee and general meetings, as well as his participation and contributions during meetings and/or discussions, the Board and NC are satisfied that he is able to devote the requisite and sufficient time and attention to the Company's affairs.

Having considered the foregoing, including but not limited to the nature and/or extent of Mr Chong's principal commitments, his professional qualifications and experience, his familiarity with the Company's affairs and the laws and regulatory compliance requirements applicable to the Company, the Board and the NC are satisfied that Mr Chong is able to devote sufficient time and attention to the Company's affairs and to discharge his duties and responsibilities effectively as an INED notwithstanding his other principal commitments and board appointments.

(b) Please clarify whether Mr. Chong has informed the Board that he intends to retire or not stand for re-election as a Director of the Company at the next AGM.

Company's Response:

The Board has not received any formal notification from Mr. Chong indicating that he intends to retire or does not intend to stand for re-election as a Director of the Company at the next AGM.

However, the Board notes that Mr. Chong has previously communicated to the Company's Executive Chairman of his intention to step down as an INED of the Company.

BY ORDER OF THE BOARD

Tan Wei Jie
Chief Executive Officer and Executive Director
13 Aug 2026

---

*This announcement has been reviewed by the Company's Sponsor, Evolve Capital Advisory Private Limited (the "**Sponsor**"). It has not been examined or approved by the Singapore Exchange Securities Trading Limited (the "**SGX-ST**"), and the SGX-ST assumes no responsibility for the contents of this document, including the correctness of any of the statements or opinions made or reports contained in this announcement.*

The contact person for the Sponsor is Mr Jerry Chua (Tel: (65) 6241 6626), at 160 Robinson Road, #20-01/02, SBF Building, Singapore 068914, Singapore 068906.